Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China

Objective: The CAMEL clinical trial (412 patients were randomly assigned to either camrelizumab plus chemotherapy (n = 205) or chemotherapy alone (n = 207)) demonstrated that camrelizumab plus chemotherapy (CC) improved the overall survival time (OS) and progression-free survival time (PFS) of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chen, Xing, Xiao-xuan, Wu, Bin, Liang, Gang, Han, Gang, Lin, Cai-xia, Fang, Hong-mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740086/
https://www.ncbi.nlm.nih.gov/pubmed/35002693
http://dx.doi.org/10.3389/fphar.2021.735536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740086/
https://www.ncbi.nlm.nih.gov/pubmed/35002693
http://dx.doi.org/10.3389/fphar.2021.735536

Ejemplares similares